Once-daily Tiotropium Respimat® Add-on to at Least ICS Maintenance Therapy Reduces Airflow Obstruction in Patients with Symptomatic Asthma, Independent of Allergic Status

Once-daily Tiotropium Respimat® Add-on to at Least ICS Maintenance Therapy Reduces Airflow Obstruction in Patients with Symptomatic Asthma, Independent of Allergic Status

Conclusions Once-daily tiotropium Respimat® add-on to at least ICS maintenance therapy reduces airflow obstruction in patients with mild to severe symptomatic asthma, independent of allergic status defined by IgE, eosinophil count, or investigator judgment.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2015-02, Vol.135 (2), p.AB6-AB6
Hauptverfasser: Murphy, Kevin R., MD, Pearlman, David S., MD, FAAAAI, Dahl, Ronald, MD, Paggiaro, Pierluigi, MD, Engel, Michael, MD, Moroni-Zentgraf, Petra, Lühmann, Reinhold, Kerstjens, Huib A.M., MD
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Asthma
Drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Conclusions Once-daily tiotropium Respimat® add-on to at least ICS maintenance therapy reduces airflow obstruction in patients with mild to severe symptomatic asthma, independent of allergic status defined by IgE, eosinophil count, or investigator judgment.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2014.12.953